MyChesCo on MSN5mon
FDA Approves New RSV Vaccine for Individuals Aged 50-59
and chronic obstructive pulmonary disease (COPD). These conditions can compromise the immune system, making it harder to ...
infectiousdiseaseadvisor.com7d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
The American Journal of Managed Care19d
GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults
Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data.
McKnight's Long-Term Care News1mon
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
Additional data from the phase 3 trial showed the vaccine came with a 94.1% effectiveness in preventing severe RSV when people got it during the first season and 64.2% a year later, the company ...
MyChesCo on MSN27d
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons
PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...
Business Wire18d
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine ... as chronic obstructive pulmonary disease (COPD ...
Medscape1mon
Pulmonary Medicine News
GSK RSV Shot 43% Effective Against Severe Disease in Third Year GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was ... to Worse Outcomes in Pulmonary Embolism Location ...
Morningstar1mon
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK’s RSV vaccine is the only RSV vaccine with efficacy ... recommending bodies determine future revaccination schedules AREXVY is the world’s first RSV vaccine and was approved based on ...
WebMD3y
Adult Vaccines Resource Center
An all-encompassing guide to understanding vaccines. CDC Recommends People Ages 50 to 64 Get Pneumococcal VaccinesThe CDC now says everyone 50 to 64 years old should get a pneumococcal vaccine to ...
Yahoo Finance12d
GSK sales hampered by slump in demand for key vaccine
Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...
Medscape1mon
Immunization - Adult Immunization News
More African Countries Set to Approve Malaria Shot African countries are lining up to approve a new vaccine for malaria, with 20 million doses available for them to buy this year. Reuters Health ...
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...